The stock of SpringWorks Therapeutics Inc (NASDAQ:SWTX) last traded at $55.13, up 2.09% from the previous session.
SWTX stock price is now 42.29% away from the 50-day moving average and 46.43% away from the 200-day moving average. The market capitalization of the company currently stands at $4.10B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $60, Evercore ISI recently initiated with Outperform rating for SpringWorks Therapeutics Inc (NASDAQ: SWTX). On February 05, 2024, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $75, while ‘BofA Securities’ rates the stock as ‘Buy’
In other news, Saqib Islam, Officer bought 137,000 shares of the company’s stock on Feb 10 ’25. The stock was bought for $7,301,552 at an average price of $53.30. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 10 ’25, Director DANIEL LYNCH bought 175,000 shares of the business’s stock. A total of $7,049,000 was incurred on buying the stock at an average price of $40.28. A total of 11.98% of the company’s stock is owned by insiders.
During the past 12 months, SpringWorks Therapeutics Inc has had a low of $28.21 and a high of $60.00. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 6.16, and a quick ratio of 6.02. The fifty day moving average price for SWTX is $38.4674 and a two-hundred day moving average price translates $37.5903 for the stock.
The latest earnings results from SpringWorks Therapeutics Inc (NASDAQ: SWTX) was released for 2024-09-30. The net profit margin was -203.09% and return on equity was -59.33% for SWTX. For the current quarter, analysts expect SWTX to generate $60.87M in revenue.
